Biofrontera

Biofrontera Stock-Based Compensation

The Stock-Based Compensation (SBC) of Biofrontera (B8FK.DE) as of Nov 21, 2026 is 508,000.00 EUR. In the previous year, Stock-Based Compensation (SBC) was 360,000.00 EUR — a change of 41.11% (higher).

Stock-Based Compensation

508,000.00EUR

YoY

41.11%

Last updated:

Stock-Based Compensation (SBC) of Biofrontera is 2020 508,000.00 EUR. Stock-Based Compensation (SBC) of Biofrontera was 2019 360,000.00 EUR. It decreases by 41.11% higher compared to the previous year.

The Biofrontera Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2019
360,000.00 EUR
Jan 1, 2020
508,000.00 EUR
The Biofrontera Stock-Based Compensation history
YEARStock-Based CompensationYoY
508,000.00EUR+41.11%
360,000.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Stock-Based Compensation (SBC) of Biofrontera is 508,000.00 EUR in 2020.

Stock-Based Compensation (SBC) of Biofrontera changed from 360,000.00 EUR to 508,000.00 EUR, representing a 41.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Biofrontera since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Biofrontera historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biofrontera

All Key Metrics — Biofrontera